TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
Publication Highlights Activity of the Combination of TRC102 and Temodar (Temozolomide) in Patients who Progressed Following Initial Treatment with Surgical Resection, Temodar and External Beam Radiotherapy
Related news for (TCON)
- TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
- TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
- TRACON Pharmaceuticals Announces Reverse Stock Split